|
시장보고서
상품코드
2008084
총상 신경섬유종 치료제 시장 : 약물 종류별, 환자층별, 유통 채널별, 지역별Plexiform Neurofibromas Treatment Market, By Drug Class, By Patient Population, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
총상 신경섬유종 치료제 시장은 2026년에 18억 8,800만 달러로 추정되며, 2033년까지 32억 6,500만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8.4%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 18억 8,800만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 8.40% | 예측 금액(2033년) | 32억 6,500만 달러 |
총상 신경섬유종은 제1형 신경섬유종증의 드문 아형으로, 여러 신경에서 발생하며 결합조직과 피부 주름까지 확장되어 부풀어 오르고 변형된 종괴를 형성합니다. 신경섬유종증은 피부, 신경, 뇌, 척수에 영향을 미칠 수 있는 유전성 신경질환입니다. 신경섬유종, 즉 종양은 체내의 신경을 따라 또는 피부 위나 아래에서 자라는 종양입니다. 신경섬유종증은 세 가지 유형으로 나뉘며, 각각 고유한 증상과 징후를 동반합니다. 제1형 신경섬유종증(NF1), 제2형 신경섬유종증(NF2), 슈반노마토시스(Schwannomatosis) 등입니다. 총상 신경섬유종은 신경섬유종증의 흔한 합병증인 제1형 신경섬유종증(NF1)의 병태생리학적 소견으로, 본질적으로 병태생리학적 소견입니다. 총상 신경섬유종은 주로 유전성 종양으로 체내 어느 부위에서나 발생할 수 있습니다. 여기에는 두경부, 사지, 척추 주변 및 장기에 영향을 미칠 수 있는 신체 깊숙한 곳도 포함됩니다. 총상 신경섬유종은 보통 유아기에 진단됩니다. NF1 환자의 약 30%에서 발견됩니다. 총상 신경섬유종은 긴 신경섬유와 그 가지에 광범위하게 퍼져 있으며, 종종 외측 신경막을 넘어 주변 조직으로 퍼져나갑니다.
시장 역학
미국 식품의약국(FDA)과 같은 규제 당국의 제품 승인과 같은 유기적 전략의 채택은 예측 기간 동안 세계 총상 신경섬유종 치료제 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2020년 4월 바이오 제약사 아스트라제네카는 미국 식품의약국(FDA)으로부터 1형 신경섬유종증 소아 환자(2세 이상)를 대상으로 '코셀루고(Koselugo)'라는 상품명으로 셀루메티닙을 승인받았다고 발표했습니다. 셀루메티닙은 키나아제 억제제이며, 신경섬유종증 소아 환자에게 승인된 최초의 치료제입니다.
본 보고서의 주요 특징
- 세계의 총상 신경섬유종 치료제 시장을 상세히 분석하고, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 신경섬유종 치료제 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 작성되었습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 신경섬유종 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 신경섬유종 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 총상 신경섬유종 치료제 시장 : 약물 종류별(2020-2033년)
제5장 세계의 총상 신경섬유종 치료제 시장 : 환자층별(2020-2033년)
제6장 세계의 총상 신경섬유종 치료제 시장 : 유통 채널별(2020-2033년)
제7장 세계의 총상 신경섬유종 치료제 시장 : 지역별(2020-2033년)
제8장 경쟁 구도
제9장 섹션
KSMPlexiform Neurofibromas Treatment Market is estimated to be valued at USD 1,888.0 Mn in 2026 and is expected to reach USD 3,265.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,888.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.40% | 2033 Value Projection: | USD 3,265.0 Mn |
Plexiform neurofibromas is an uncommon variant of neurofibromatosis type 1 that arises from multiple nerves as bulging and deforming masses involving also connective tissue and skin folds. Neurofibromatosis is a genetic neurological disorder which can affect the skin, nerves, brain, and spinal cord. Neurofibromas or tumors, grow along the body's nerves or on or underneath the skin. There are three types of neurofibromatosis that are associated with unique symptoms and signs, Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and Schwannomatosis. Plexiform neurofibromas are essentially pathognomonic of neurofibromatosis type 1 (NF1) which is a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Plexiform neurofibromas are usually diagnosed in early childhood. They are found in approximately 30% of patients with NF1. Plexiform neurofibromas diffusely involve long nerve segments and its branches, often extending beyond the epineurium into the surrounding tissue.
Market Dynamics
Adoption of inorganic strategies, such as product approval, by regulatory authority such as the U.S. Food and Drug Administration is expected to drive the global plexiform neurofibromas treatment market growth over the forecast period. For instance, in April 2020, AstraZeneca, a biopharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Selumetinib under the brand name Koselugo, for pediatric patients, 2 years of age and older, with neurofibromatosis type 1. Selumetinib is a kinase inhibitor and the first therapy approved for pediatric patients with neurofibromatosis.
Key features of the study
- This report provides an in-depth analysis of the global plexiform neurofibromas treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global plexiform neurofibromas treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global plexiform neurofibromas treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plexiform neurofibromas treatment market
Market Segmentation
- By Drug Class (Revenue, USD Mn, 2020 - 2033)
- Selumetinib
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Anticonvulsants
- Others (Tricyclic Antidepressants, etc.)
- By Application Insights (Revenue, USD Mn, 2020 - 2033)
- Pediatric
- Adult
- By End User Insights (Revenue, USD Mn, 2020 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- AstraZeneca
- Pfizer Inc.
- Sun Pharmaceuticals Industries Limited
- Mallinckrodt Pharmaceuticals
- SpringWorks Therapeutics
- Alcaliber S.A
- Teva Pharmaceutical Industries Ltd.
- Glenmark, Amneal Pharmaceuticals LLC
- Aurobindo Pharma
- Apotex Inc.
- Mylan N.V.
- GSK plc.
- Solara Active Pharma Sciences Ltd.
- Abbott
- Shanghai Kechow Pharma, Inc.
- Endo Pharmaceuticals Inc.
- Purdue Pharma L.P.
- Merck & Co., Inc.
- NFlection Therapeutics
- Healx
- Array Biopharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Patient Population
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- PEST Analysis
- PORTER's Analysis
- Key Developments
- Brand Analysis
- Merger and Collaboration Scenario
- Epidemiology
- Product Approvals/Launches
- Treatment Algorithm
- Treatment Option Analysis
- Site of Activity (Mode of Action)
- New Investments by Major Market Players
- Manufacturer Revenue
- Disease Awareness Programs
- Healthcare Spending by Country
4. Global Plexiform Neurofibromas Treatment Market, By Drug Class, 2020-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2020-2033
- Segment Trends
- Selumetinib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Anticonvulsants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Others (Tricyclic Antidepressants, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
5. Global Plexiform Neurofibromas Treatment Market, By Patient Population, 2020-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2020-2033
- Segment Trends
- Pediatric
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Adult
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
6. Global Plexiform Neurofibromas Treatment Market, By Distribution Channel, 2020-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2020-2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
7. Global Plexiform Neurofibromas Treatment Market, By Region, 2020-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- U.S.
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Canada
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- Brazil
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Mexico
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Argentina
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Rest of Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- U.K.
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Germany
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Italy
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- France
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Spain
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Russia
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Rest of Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- China
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- India
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Japan
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- ASEAN
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Australia
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- South Korea
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Rest of Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- GCC
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Israel
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Rest of Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2033, (USD Mn)
- North Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Central Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- South Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
8. Competitive Landscape
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceuticals Industries Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mallinckrodt Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SpringWorks Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alcaliber S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Glenmark
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amneal Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Solara Active Pharma Sciences Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Shanghai Kechow Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Endo Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Purdue Pharma L.P
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NFlection Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Healx
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Array Biopharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
샘플 요청 목록